Nati Lerman

Oncology

3 Cooper Plz Rm 215
Camden, NJ 08103

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

Clinical and economic burden of recurrence among older patients with locoregionally advanced head and neck squamous cell carcinoma in the United States.

Clinical and economic burden of recurrence among older patients with locoregionally advanced head and neck squamous cell carcinoma in the United States.

Journal: Journal of managed care & specialty pharmacy

Published: May 21, 2026

Correction: Real-world treatment patterns and clinical outcomes among elderly patients with locoregionally advanced head and neck squamous cell carcinoma in the United States.

Correction: Real-world treatment patterns and clinical outcomes among elderly patients with locoregionally advanced head and neck squamous cell carcinoma in the United States.

Journal: Frontiers in oncology

Published: February 05, 2026

Corrigendum to "PD-L1 testing patterns in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) in the U.S." [Oral Oncol. 161 (2025) 107146].

Corrigendum to "PD-L1 testing patterns in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) in the U.S." [Oral Oncol. 161 (2025) 107146].

Journal: Oral oncology

Published: April 12, 2025

Real-world treatment patterns and clinical outcomes among elderly patients with locoregionally advanced head and neck squamous cell carcinoma in the United States.

Real-world treatment patterns and clinical outcomes among elderly patients with locoregionally advanced head and neck squamous cell carcinoma in the United States.

Journal: Frontiers in oncology

Published: April 06, 2025

Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: 5-year follow-up from the randomized phase III KEYNOTE-048 study.

Pembrolizumab with or without chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma: 5-year follow-up from the randomized phase III KEYNOTE-048 study.

Journal: European journal of cancer (Oxford, England : 1990)

Published: December 16, 2024

PD-L1 testing patterns in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) in the U.S.

PD-L1 testing patterns in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) in the U.S.

Journal: Oral oncology

Published: August 22, 2024

First-line pembrolizumab with or without chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: 5-year follow-up of the Japanese population of KEYNOTE‑048.

First-line pembrolizumab with or without chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: 5-year follow-up of the Japanese population of KEYNOTE‑048.

Journal: International journal of clinical oncology

Published: June 27, 2024

Real-world use of first-line pembrolizumab + platinum + taxane combination regimens in recurrent / metastatic head and neck squamous cell carcinoma.

Real-world use of first-line pembrolizumab + platinum + taxane combination regimens in recurrent / metastatic head and neck squamous cell carcinoma.

Journal: Frontiers in oncology

Published: December 01, 2023

Pembrolizumab versus methotrexate, docetaxel, or cetuximab in recurrent or metastatic head and neck squamous cell carcinoma (KEYNOTE-040): Subgroup analysis by pattern of disease recurrence.

Pembrolizumab versus methotrexate, docetaxel, or cetuximab in recurrent or metastatic head and neck squamous cell carcinoma (KEYNOTE-040): Subgroup analysis by pattern of disease recurrence.

Journal: Oral oncology

Published: April 25, 2023

Olaparib with or without bevacizumab or bevacizumab and 5-fluorouracil in advanced colorectal cancer: Phase III LYNK-003.

Olaparib with or without bevacizumab or bevacizumab and 5-fluorouracil in advanced colorectal cancer: Phase III LYNK-003.

Journal: Future oncology (London, England)

Published: November 15, 2021

High grade sarcoma, with predominant neuroectodermal and minor embryonal rhabdomyosarcomatous tumor of the uterus: A case report.

High grade sarcoma, with predominant neuroectodermal and minor embryonal rhabdomyosarcomatous tumor of the uterus: A case report.

Journal: Gynecologic oncology reports

Published: February 22, 2019

Radiologic images of an aggressive implant-associated fibromatosis of the breast and chest wall: case report and review of the literature.

Radiologic images of an aggressive implant-associated fibromatosis of the breast and chest wall: case report and review of the literature.

Journal: Radiology case reports

Published: March 19, 2017

Showing 1-12 of 14

Last Updated: 09/26/2026